Apparent Mineralocorticoid Excess (AME) Syndrome

Indian Pediatrics

Volumn 50, Issue 4, 2013, Pages 416-418

  Parvez, Yusuf ^a   El Sayed, Ola ^a  

^a AL JAHRA HOSPITAL   (Kuwait)

Author keywords

11 hydroxysteroid dehydrogenase type2 enzyme; Hypertension; Mutation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALLOTETRAHYDROCORTISOL; AMILORIDE; POTASSIUM; RENIN; SPIRONOLACTONE; STEROID; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BARTTER SYNDROME; CASE REPORT; CHILD; CHROMATOGRAPHY; CLINICAL FEATURE; DISEASE ASSOCIATION; DYSTROPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; GENE; HSD11B2 GENE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFANT; KIDNEY CALCIFICATION; LOW BIRTH WEIGHT; MEDICAL HISTORY; METABOLIC ALKALOSIS; MISSENSE MUTATION; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRESSURE MEASUREMENT; STEROID URINE LEVEL; STRABISMUS; WHEEZING;

EID: 84885774227     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-013-0100-6     Document Type: Article

References (10)

1. Craigie E., Evans L.C., Mullins J.J., Bailey M.A. Failure to downregulate the epithelial sodium channel causes salt sensitivity in hsd 11 b2 heterozygote mice. Hypertension. 2012; 60:684-690.
2. Knops N.B., Monnens L.A., Lenders J.W., Levtchenko E.N. Apparent mineralocorticoid excess: time of manifestation and complications despite treatment. Pediatrics. 2011; 127:e1610-4.
3. Morineau G., Sulmont V., Salomon R., Fiquet-Kempf B., Jeunemaître X., Nicod J., et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal Experience. J Am Soc Nephrol. 2006; 17:3176-3184.
4. Kamide K., Kokubo Y., Hanada H., Nagura J., Yang J., Takiuchi S., et al. Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens Res. 2006; 29:243-252.
5. Hassan-Smith Z., Stewart P.M. Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011; 18:177-185.
6. Martinez-Aguayo A., Fardella C. Genetics of hypertensive syndrome. Horm Res. 2009; 71:253-259.
7. Moudgil A., Rodich G., Jordan S.C., Kamil E.S. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome. Pediatr Nephrol. 2000; 15:60-62.
8. Stewart P.M., Corrie J.E., Shackleton C.H., Edwards C.R. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 1988; 82: 340-349.
9. Ferrari P., Krozowski Z. Role of the 11 beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int. 200; 57:1374-1381.
10. Khosla N., Hogan D. Mineralocorticoid hypertension and hypokalemia. Semin Nephrol. 2006; 26:434-440.